One canonical landing per dataset
Each release has one page for scope, definitions, dates, methods, downloads, and citation. CSV and JSON remain distributions, not competing indexed copies.
Peptide Local public evidence data6460 records.
6460 records.
One research desk.
Browse every public Peptide Local dataset from one canonical catalog. Each release has a human-readable landing page, explicit evidence boundary, data dictionary, review date, source provenance, and clean CSV and JSON downloads.
Reusable evidence records with their limits attached.The catalog separates source-registry records, normalized weight-loss trial-result observations, clinical-trial registry records, search-trend observations, seller price observations, seller document-access routes, public batch-report fields, nightly price-source outcomes, provider market candidates, transparency pilot assessments, jurisdiction metadata, compound-country records, US state records, Canadian province records, Australian jurisdiction records, and regulator routes. Combining them does not turn any row into laboratory proof, legal advice, medical guidance, product authorization, enrollment eligibility, or seller certification.
Catalog principles
Data that can be inspected, cited, and corrected.
Every download comes from the same maintained records as its HTML landing page. The page preserves definitions and caveats that a raw row cannot carry alone.
Source provenance stays visible
Price rows retain seller URLs. Location rows retain official jurisdiction sources. Country, province, and state rows retain identity, product, pharmacy, and supply records. Regulator rows retain the exact public authority and source purpose.
Corrections update every format
The HTML ledger and both downloads are generated from the same source records. A reviewed correction cannot silently change only one public representation.
Public dataset inventory
19 different questions. 19 bounded datasets.
Choose the dataset that matches the question. Source provenance, trial status, search interest, published prices, seller document access, public report fields, price-source freshness, provider candidates, transparency scores, jurisdiction metadata, official regulator routes, country checks, Canadian province checks, US state checks, and Australian jurisdiction checks should not be normalized into one conclusion.
CurrentReviewed 4 days before this releasemonthly policy · 30-day window · due 2026-08-23
FDA medicine, worldwide clinical pipeline, and US research-market profile recordsPeptide evidence and status index
40 canonical peptide and GLP-1 records across FDA-approved medicines, investigational clinical programs, and qualified US research-market boards, with 139 aliases, 211 linked evidence records, status, checked dates, profile paths, primary publishers, and direct source URLs.
- Rows
- 40
- Aliases
- 139
- Evidence routes
- 211
- Categories
- 3
Boundary
A source-routing and identity dataset across three different evidence categories. Record count and linked-source count do not measure clinical strength, safety, efficacy, product quality, legal access, or suitability for use.
CurrentReviewed 2 days before this releasemonthly policy · 30-day window · due 2026-08-25
Site-wide public evidence sources and their dated internal citation routesPeptide evidence source registry
815 deduplicated official, clinical, independent-testing, commercial, and reputation sources with 2615 dated citation uses across 306 public Peptide Local pages, preserving publisher, source URL, evidence family, citation purpose, latest check, review age, and freshness band.
- Rows
- 815
- Publishers
- 190
- Page citations
- 2615
- Cited pages
- 306
Boundary
A source record proves only that Peptide Local cited the linked public record for the stated page, evidence family, purpose, and checked date. Source inclusion, citation frequency, and publisher coverage are not quality scores, endorsements, medical guidance, legal conclusions, product authentication, or provider certification.
CurrentReviewed 7 days before this releasemonthly policy · 30-day window · due 2026-08-20
Selected obesity and overweight trial observations across investigational and China-approved programsWeight-loss drug trial results
15 source-linked observations across 13 tracked weight-loss drug programs, preserving trial duration, phase, route, population, comparator, result basis, estimand, ClinicalTrials.gov study design, registry status, regulatory status, and direct source routes.
- Rows
- 15
- Programs
- 13
- Trial observations
- 15
- Direct evidence routes
- 28
Boundary
A source-linked orientation dataset of selected reported mean body-weight results from separate clinical trials. Differences in population, duration, dose, route, phase, estimand, adherence assumptions, rescue treatment, missing-data handling, comparator response, and source maturity prevent a cross-trial efficacy or safety ranking. A chart position is not a treatment recommendation, approval, individual prediction, or head-to-head result.
CurrentReviewed with this catalog releasenightly policy · 2-day window · due 2026-07-30
Worldwide registry records across thirteen peptide and next-generation weight-loss programsPeptide clinical trial registry
268 deduplicated ClinicalTrials.gov records across 13 tracked peptide and next-generation weight-loss programs, preserving overall status, individual-site recruitment counts, phase, sponsor, enrollment, completion dates, results availability, 53 countries, 1,840 recruiting cities, postal areas, registry geocoordinates, and direct NCT source URLs.
- Rows
- 268
- Programs
- 13
- Recruiting records
- 61
- Recruiting cities
- 1840
Boundary
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
CurrentReviewed with this catalog releasenightly policy · 2-day window · due 2026-07-30
Worldwide retatrutide intervention-search records that are open-program or activeRetatrutide clinical-trial tracker
14 open-program records from a 34-match ClinicalTrials.gov intervention search, separating Recruiting, Active not recruiting, and Available expanded-access statuses with locations, countries, enrollment, dates, sponsor, and an evidence boundary for every record.
- Rows
- 14
- Registry matches
- 34
- Recruiting records
- 2
- Countries with recruiting sites
- 27
Boundary
A dated transformation of ClinicalTrials.gov intervention-search records. Overall study status, listed locations, estimated enrollment, and completion dates can change. A recruiting study may contain individual sites that are not open, and a listed location does not establish eligibility, enrollment, treatment access, FDA approval, or routine availability.
CurrentReviewed 8 days before this releasestrategic policy · 45-day window · due 2026-09-03
United States and worldwide Google Trends observationsUS and worldwide peptide search trends
184 dated Google Trends observations across 36 separate US and worldwide panels covering peptide therapy, weight-loss peptides, core names, emerging metabolic programs, research peptides, retatrutide, cagrilintide, GHK-Cu, ipamorelin, and KPV intent, plus high-index regions.
- Rows
- 184
- Trend panels
- 36
- Observations
- 184
- Geographies
- US + worldwide
Boundary
A dated Google Trends observation, not keyword search volume, market size, medical demand, product availability, legal status, or a forecast. Values are normalized within each exact panel and cannot be compared across panels.
CurrentReviewed 1 day before this releaseweekly policy · 14-day window · due 2026-08-10
United States research-market observationsUS research peptide price index
A dated snapshot of 78 public US laboratory research listings across 20 exact-size boards and 7 sellers, with stable product and vendor slugs, currency, observed price, availability, source URL, evidence status, regional applicability, review date, and exact-record retrieval.
- Rows
- 78
- Products
- 20
- Vendors
- 7
- Available rows
- 54
Boundary
Seller-page observations for US research-material comparison only. Price, labelled size, availability, shipping, and evidence access are commercial-source fields, not independent laboratory findings, medical-product claims, destination eligibility, delivery confirmation, or seller certification.
CurrentReviewed 1 day before this releaseweekly policy · 14-day window · due 2026-08-10
Seller-published document access for exact-size United States research-market listingsPeptide COA and seller document access index
78 exact-size seller rows across 20 research peptide boards and 7 sellers, separating 57 public report routes, 5 documents included with an order, and 16 routes available only after seller contact, with limitation notes, checked dates, audit paths, and canonical sources.
- Rows
- 78
- Public links
- 57
- Included with order
- 5
- On request
- 16
Boundary
These rows record seller-published document access observed from exact listing pages. A public link, report label, document included with an order, or response to a request does not authenticate a report, connect it to a supplied vial, establish chain of custody, or independently confirm identity, purity, quantity, sterility, safety, legality, or suitability for use.
CurrentReviewed 7 days before this releasemonthly policy · 30-day window · due 2026-08-20
Public seller report indexes for United States research-market listingsPublic peptide COA and batch report ledger
101 public report routes across 17 peptide names, 2 seller indexes, and 7 named laboratories, preserving displayed batch, variant, date, quantity, purity, endotoxin, verification-key, document-host, and source-index fields without converting a published document into a product or custody verdict.
- Rows
- 101
- Products
- 17
- Named laboratories
- 7
- Lab verification routes
- 22
Boundary
This ledger transcribes fields displayed in public seller report indexes and links the underlying documents. A laboratory name, batch identifier, purity value, quantity result, seller-hosted file, or laboratory verification page does not establish how a retail vial was selected, whether the submitted sample represents inventory, or whether a later supplied item shares its identity, contents, custody, sterility, safety, legality, or suitability for use.
CurrentReviewed with this catalog releasenightly policy · 2-day window · due 2026-07-30
Current source health for the United States research peptide price indexUS peptide price source monitor
78 current exact-product source checks across 20 peptide boards and 7 sellers, preserving published price, availability, fetch time, monitor status, candidate value, parser confidence, consecutive runs, review reason, source URL, and freshness status for every row.
- Rows
- 78
- Confirmed rows
- 78
- Review items
- 0
- Stale rows
- 0
Boundary
Automated source checks test whether a current public seller source supports the exact-product price and returns a reliable availability signal. The canonical product page remains the published listing source. When that page blocks automation, the monitor may use the seller's public WooCommerce Store API and discloses that transport separately. A confirmed result does not verify product contents, quality, purity, sterility, safety, legality, seller reliability, or suitability for use. A blocked or review result does not prove a listing is wrong; it means the automated check could not safely reconfirm it.
CurrentReviewed 7 days before this releaseevent driven policy · 30-day window · due 2026-08-20
Dated changes within the United States research-market price indexUS research peptide price change log
14 accepted exact-product price changes inside 1 seller and date cluster, with previous and current list prices, movement, repeated-check count, publication availability, current board position, cluster ID, and direct source URL.
- Rows
- 14
- Price changes
- 14
- Products
- 14
- Vendors
- 1
Boundary
A dated comparison of Peptide Local's previous published seller-page observation with the current public seller page. The current release contains one seller and date cluster, so its rows are not independent evidence of a market-wide trend. It is not a complete market history, transaction price, product-quality finding, or medical-product claim.
CurrentReviewed 2 days before this releaseweekly policy · 14-day window · due 2026-08-09
United States and US-facing research peptide provider candidatesProvider market scan
16 sourced candidate records with third-party test coverage, blind sample evidence, tested-product coverage, evidence method, method limits, current stage, source routes, storefront routes, and a required next verification check.
- Rows
- 16
- Candidates
- 16
- External evidence rows
- 15
- Overall winners
- 0
Boundary
A candidate-discovery and evidence-triage dataset, not a provider endorsement, safety certification, or finding about every product or future batch. Test findings remain specific to the cited source, peptide, sample, and date.
CurrentReviewed 9 days before this releasequarterly policy · 100-day window · due 2026-10-27
Seven sellers already present in the United States price datasetProvider transparency pilot
7 retained pilot records with seven category scores, withdrawn badge status, source URLs, checked date, correction state, and a required market-scope boundary.
- Rows
- 7
- Providers
- 7
- Categories
- 7
- Active badges
- 0
Boundary
A seven-provider price-tracking pilot, not a complete market sample or a finding about product identity, purity, quantity, sterility, safety, legality, regulatory approval, or fitness for use.
CurrentReviewed 10 days before this releasequarterly policy · 90-day window · due 2026-10-16
Countries, Canadian provinces, US states, Australian regions, and citiesRegional access and verification index
143 country, Canadian province, US state, Australian region, and city guide records with content language, market status, comparison access, review date, and official source URLs.
- Rows
- 143
- Countries
- 42
- Subnational regions
- 68
- Cities
- 33
Boundary
A jurisdiction and source-routing index, not a blanket legal determination, product approval, seller verification, or availability finding.
CurrentReviewed 4 days before this releasequarterly policy · 90-day window · due 2026-10-22
41 compounds across 42 countries and five regionsGlobal compound-country verification index
1722 sourced rows connecting 41 tracked compound identities to 42 countries, five regions, 22 languages, official product and seller records, and an explicit evidence-depth label for every status summary.
- Rows
- 1722
- Compounds
- 41
- Countries
- 42
- Sourced compound-country statuses
- 43
Boundary
A compound-identity and destination source map, not a legal, medical, availability, quality, or seller-certification conclusion.
CurrentReviewed 8 days before this releasequarterly policy · 90-day window · due 2026-10-18
41 compounds across 50 US statesUS compound-state verification atlas
2050 sourced rows connecting 41 tracked compound identities to 50 US state pharmacy routes, supporting official records, and canonical atlas sections.
- Rows
- 2050
- Compounds
- 41
- US states
- 50
- Source URLs
- 96
Boundary
A compound-identity and state source map, not a legal, medical, availability, quality, compounding, prescription, or seller-certification conclusion.
CurrentReviewed 10 days before this releasequarterly policy · 90-day window · due 2026-10-16
Official medicine, regulator, seller, facility, safety, and supply routes across 42 countriesOfficial regulator and medicine database directory
99 unique official URLs across 42 countries, classified as medicine and product records, seller and facility checks, or safety and supply guidance, with publisher and review date attached.
- Rows
- 99
- Countries
- 42
- Publishers
- 57
- Languages
- 22
Boundary
An official source-finding directory, not a legal-status verdict, product authorization finding, medical recommendation, seller certification, supply permission, or substitute for the current record.
CurrentReviewed 8 days before this releasequarterly policy · 90-day window · due 2026-10-18
41 compounds across 10 Canadian provincesCanada compound-province verification atlas
410 sourced rows connecting 41 tracked compound identities to 10 Canadian province pharmacy routes, Health Canada product records, and canonical atlas sections.
- Rows
- 410
- Compounds
- 41
- Canadian provinces
- 10
- Source URLs
- 38
Boundary
A compound-identity, federal-product, and province source map, not a legal, medical, availability, quality, compounding, prescription, import, or seller-certification conclusion.
CurrentReviewed 8 days before this releasequarterly policy · 90-day window · due 2026-10-18
41 compounds across all Australian states and territoriesAustralia compound-jurisdiction verification atlas
328 sourced rows connecting 41 tracked compound identities to all 8 Australian states and territories, official local routes, ARTG records, and canonical atlas sections.
- Rows
- 328
- Compounds
- 41
- States and territories
- 8
- Source URLs
- 36
Boundary
A compound-identity, national-product, practitioner, and jurisdiction source map, not a legal, medical, availability, quality, compounding, prescription, import, or seller-certification conclusion.
Coverage matrix
Know what each release can answer.
The fastest way to misuse data is to ask it a question outside its scope. Source provenance, peptide status, trial status, search interest, published prices, price-source freshness, provider evidence, and local verification routes are separate questions. This matrix keeps each publication boundary next to its coverage.
| Dataset | Records | Freshness | Scope | Review cadence | Provenance | Formats |
|---|---|---|---|---|---|---|
| Peptide evidence and status indexVersion 2026-07-24 | 40 | Current4d old · due 2026-08-23 | FDA medicine, worldwide clinical pipeline, and US research-market profile records | Dated profile and primary-source review when an evidence record changes | A source-routing and identity dataset across three different evidence categories. Record count and linked-source count do not measure clinical strength, safety, efficacy, product quality, legal access, or suitability for use. | CSV ↘JSON ↘ |
| Peptide evidence source registryVersion 2026-07-26 | 815 | Current2d old · due 2026-08-25 | Site-wide public evidence sources and their dated internal citation routes | Generated from canonical site records with a dated review whenever a cited record changes | A source record proves only that Peptide Local cited the linked public record for the stated page, evidence family, purpose, and checked date. Source inclusion, citation frequency, and publisher coverage are not quality scores, endorsements, medical guidance, legal conclusions, product authentication, or provider certification. | CSV ↘JSON ↘ |
| Weight-loss drug trial resultsVersion 2026-07-21 | 15 | Current7d old · due 2026-08-20 | Selected obesity and overweight trial observations across investigational and China-approved programs | Dated primary-source review when a trial publication, sponsor result, or regulatory record changes | A source-linked orientation dataset of selected reported mean body-weight results from separate clinical trials. Differences in population, duration, dose, route, phase, estimand, adherence assumptions, rescue treatment, missing-data handling, comparator response, and source maturity prevent a cross-trial efficacy or safety ranking. A chart position is not a treatment recommendation, approval, individual prediction, or head-to-head result. | CSV ↘JSON ↘ |
| Peptide clinical trial registryVersion 2026-07-24 | 268 | Current0d old · due 2026-07-30 | Worldwide registry records across thirteen peptide and next-generation weight-loss programs | Dated ClinicalTrials.gov API refresh with exact intervention aliases and NCT deduplication | A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion. | CSV ↘JSON ↘ |
| Retatrutide clinical-trial trackerVersion 2026-07-24 | 14 | Current0d old · due 2026-07-30 | Worldwide retatrutide intervention-search records that are open-program or active | Dated ClinicalTrials.gov status and location review | A dated transformation of ClinicalTrials.gov intervention-search records. Overall study status, listed locations, estimated enrollment, and completion dates can change. A recruiting study may contain individual sites that are not open, and a listed location does not establish eligibility, enrollment, treatment access, FDA approval, or routine availability. | CSV ↘JSON ↘ |
| US and worldwide peptide search trendsVersion 2026-07-20 | 184 | Current8d old · due 2026-09-03 | United States and worldwide Google Trends observations | Dated strategic refresh as search patterns and program names change | A dated Google Trends observation, not keyword search volume, market size, medical demand, product availability, legal status, or a forecast. Values are normalized within each exact panel and cannot be compared across panels. | CSV ↘JSON ↘ |
| US research peptide price indexVersion 2026-07-27 | 78 | Current1d old · due 2026-08-10 | United States research-market observations | Weekly source review with a 14-day publication window | Seller-page observations for US research-material comparison only. Price, labelled size, availability, shipping, and evidence access are commercial-source fields, not independent laboratory findings, medical-product claims, destination eligibility, delivery confirmation, or seller certification. | CSV ↘JSON ↘Record API → |
| Peptide COA and seller document access indexVersion 2026-07-27 | 78 | Current1d old · due 2026-08-10 | Seller-published document access for exact-size United States research-market listings | Weekly exact-listing source review with the underlying qualified price-index release | These rows record seller-published document access observed from exact listing pages. A public link, report label, document included with an order, or response to a request does not authenticate a report, connect it to a supplied vial, establish chain of custody, or independently confirm identity, purity, quantity, sterility, safety, legality, or suitability for use. | CSV ↘JSON ↘ |
| Public peptide COA and batch report ledgerVersion 2026-07-21 | 101 | Current7d old · due 2026-08-20 | Public seller report indexes for United States research-market listings | Dated seller-index refresh with publication gates for required fields, unique document routes, and direct HTTPS sources | This ledger transcribes fields displayed in public seller report indexes and links the underlying documents. A laboratory name, batch identifier, purity value, quantity result, seller-hosted file, or laboratory verification page does not establish how a retail vial was selected, whether the submitted sample represents inventory, or whether a later supplied item shares its identity, contents, custody, sterility, safety, legality, or suitability for use. | CSV ↘JSON ↘ |
| US peptide price source monitorVersion 2026-07-27 | 78 | Current0d old · due 2026-07-30 | Current source health for the United States research peptide price index | Nightly source monitoring with manual reconciliation before any public price change | Automated source checks test whether a current public seller source supports the exact-product price and returns a reliable availability signal. The canonical product page remains the published listing source. When that page blocks automation, the monitor may use the seller's public WooCommerce Store API and discloses that transport separately. A confirmed result does not verify product contents, quality, purity, sterility, safety, legality, seller reliability, or suitability for use. A blocked or review result does not prove a listing is wrong; it means the automated check could not safely reconfirm it. | CSV ↘JSON ↘ |
| US research peptide price change logVersion 2026-07-21 | 14 | Current7d old · due 2026-08-20 | Dated changes within the United States research-market price index | Nightly candidate checks with repeated-source confirmation and editorial publication | A dated comparison of Peptide Local's previous published seller-page observation with the current public seller page. The current release contains one seller and date cluster, so its rows are not independent evidence of a market-wide trend. It is not a complete market history, transaction price, product-quality finding, or medical-product claim. | CSV ↘JSON ↘ |
| Provider market scanVersion 2026-07-26 | 16 | Current2d old · due 2026-08-09 | United States and US-facing research peptide provider candidates | Continuous candidate discovery with dated evidence reconciliation | A candidate-discovery and evidence-triage dataset, not a provider endorsement, safety certification, or finding about every product or future batch. Test findings remain specific to the cited source, peptide, sample, and date. | CSV ↘JSON ↘ |
| Provider transparency pilotVersion 2026-07-19 | 7 | Current9d old · due 2026-10-27 | Seven sellers already present in the United States price dataset | Quarterly source review plus correction-triggered reassessment | A seven-provider price-tracking pilot, not a complete market sample or a finding about product identity, purity, quantity, sterility, safety, legality, regulatory approval, or fitness for use. | CSV ↘JSON ↘ |
| Regional access and verification indexVersion 2026-07-18 | 143 | Current10d old · due 2026-10-16 | Countries, Canadian provinces, US states, Australian regions, and cities | Dated editorial review when jurisdiction records change | A jurisdiction and source-routing index, not a blanket legal determination, product approval, seller verification, or availability finding. | CSV ↘JSON ↘ |
| Global compound-country verification indexVersion 2026-07-24 | 1722 | Current4d old · due 2026-10-22 | 41 compounds across 42 countries and five regions | Dated compound-identity and country-source review | A compound-identity and destination source map, not a legal, medical, availability, quality, or seller-certification conclusion. | CSV ↘JSON ↘Record API → |
| US compound-state verification atlasVersion 2026-07-20 | 2050 | Current8d old · due 2026-10-18 | 41 compounds across 50 US states | Dated compound-identity and state-source review | A compound-identity and state source map, not a legal, medical, availability, quality, compounding, prescription, or seller-certification conclusion. | CSV ↘JSON ↘ |
| Official regulator and medicine database directoryVersion 2026-07-18 | 99 | Current10d old · due 2026-10-16 | Official medicine, regulator, seller, facility, safety, and supply routes across 42 countries | Dated editorial review when an official country source changes | An official source-finding directory, not a legal-status verdict, product authorization finding, medical recommendation, seller certification, supply permission, or substitute for the current record. | CSV ↘JSON ↘ |
| Canada compound-province verification atlasVersion 2026-07-20 | 410 | Current8d old · due 2026-10-18 | 41 compounds across 10 Canadian provinces | Dated compound-identity, federal-product, and province-source review | A compound-identity, federal-product, and province source map, not a legal, medical, availability, quality, compounding, prescription, import, or seller-certification conclusion. | CSV ↘JSON ↘ |
| Australia compound-jurisdiction verification atlasVersion 2026-07-20 | 328 | Current8d old · due 2026-10-18 | 41 compounds across all Australian states and territories | Dated compound-identity, ARTG, and jurisdiction-source review | A compound-identity, national-product, practitioner, and jurisdiction source map, not a legal, medical, availability, quality, compounding, prescription, import, or seller-certification conclusion. | CSV ↘JSON ↘ |
Use and citation
Link the evidence page, not just the file.
Use the canonical landing page when citing a dataset. It carries the current version, scope, definitions, source method, safety boundary, and correction route that a downloaded row cannot fully express.
Every dataset is free to inspect and download. Contact the editorial desk for corrections, press questions, research collaboration, bulk-use questions, or a requested field definition.
Read the publication method →Audit the source registry →Read the data license →Contact the data desk →